Mukthinuthalapati VVPK, et al. - In order to present a single institution experience with sorafenib for the treatment of patients with hepatocellular carcinoma (HCC), researchers retrospectively analyzed electronic medical records of patients with HCC (confirmed with radiographic criteria and/or biopsy) who received sorafenib from 2009 to 2016. They identified lower overall survival of patients with HCC treated with sorafenib in the United States vs individuals from Europe or Japan. They found that, in those treated with sorafenib for HCC, hepatitis C virus infection may be a marker of benefit.